{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:57:50Z","timestamp":1791176270433,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T00:00:00Z","timestamp":1380499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Interleukin (IL)28B polymorphisms are associated with spontaneous clearance of hepatitis C virus (HCV) infection and response to therapy. Whether IL28B genotype affects fibrosis progression or clinical outcome is unclear. Our aim was to study the relationship between IL28B genotype and both histological and clinical outcomes in patients with chronic hepatitis C (CHC). Hepatic fibrosis was scored using the Ishak (0-6) scale; progression was defined as a 2-point increase in Ishak score between biopsies. Multiple logistic and Cox regressions were used to identify variables associated with fibrosis progression. In all, 1,483 patients were included in a baseline cross-sectional analysis, from which 276 were eligible for a paired biopsy analysis (median time between biopsies 4 years), and 400 for a clinical outcome analysis. At baseline biopsy, patients with IL28B CC genotype had significantly higher portal inflammation (2.4 versus 2.2) and alanine aminotransferase (ALT) levels (133 versus 105 U\/L;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>&lt; 0.05 for all). In the paired biopsy analysis, there was no difference in the frequency of fibrosis progression between patients with IL28B CC and non-CC genotypes (17% versus 23%). In logistic regression, only higher baseline alkaline phosphatase, lower platelets, and greater hepatic steatosis were associated with fibrosis progression. Patients with IL28B CC were twice as likely to develop adverse clinical outcomes compared to non-CC (32% versus 16%;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.007).<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>\n                                 <jats:bold>IL28B CC genotype was associated with greater hepatic necroinflammation, higher ALT, and worse clinical outcomes in CHC patients. This suggests that IL28B CC is associated with a state of enhanced immunity that, on the one hand, can promote viral clearance, but alternately can increase necroinflammation and hepatic decompensation without enhancing fibrosis progression. (Hepatology 2013;58:1548\u20131557)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26506","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T20:51:20Z","timestamp":1369342280000},"page":"1548-1557","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":96,"title":["Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis"],"prefix":"10.1097","volume":"58","author":[{"given":"Mazen","family":"Noureddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey J.","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongce","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Conry-Cantilena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Kleiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake T.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Ghany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20241201","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-132-4-200002150-00008","article-title":"Pathogenesis, natural history, treatment, and prevention of hepatitis C.","volume":"132","author":"Liang","year":"2000","journal-title":"Ann Intern Med"},{"key":"R3-6-20241201","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1002\/hep.510260711","article-title":"Epidemiology of hepatitis C.","volume":"26","author":"Alter","year":"1997","journal-title":"Hepatology"},{"key":"R4-6-20241201","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clinre.2011.03.006","article-title":"Has genetics eradicated the good old predictors of hepatitis C treatment response?","volume":"35","author":"Pawlotsky","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R5-6-20241201","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/hep.23947","article-title":"Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa2aribavirin in chronic hepatitis C.","volume":"52","author":"Chung","year":"2010","journal-title":"Hepatology"},{"key":"R6-6-20241201","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance.","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"R7-6-20241201","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genomewide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C.","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"R8-6-20241201","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy.","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"R9-6-20241201","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"R11-6-20241201","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jhep.2010.07.019","article-title":"IL28B rs12979860 CT allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.","volume":"54","author":"Fabris","year":"2011","journal-title":"J Hepatol"},{"key":"R12-6-20241201","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jhep.2010.03.022","article-title":"Common variation of IL28 affects gammaGTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.","volume":"53","author":"Abe","year":"2010","journal-title":"J Hepatol"},{"key":"R13-6-20241201","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.24503","article-title":"Genetic variation in the interleukin28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection.","volume":"54","author":"Marabita","year":"2011","journal-title":"Hepatology"},{"key":"R14-6-20241201","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/gast.2003.50018","article-title":"Progression of fibrosis in chronic hepatitis C.","volume":"124","author":"Ghany","year":"2003","journal-title":"Gastroenterology"},{"key":"R15-6-20241201","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","article-title":"Prolonged therapy of advanced chronic hepatitis C with lowdose peginterferon.","volume":"359","author":"Di Bisceglie","year":"2008","journal-title":"N Engl J Med"},{"key":"R16-6-20241201","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis.","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"R17-6-20241201","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1101\/gr.10.2.258","article-title":"Highthroughput SNP allelefrequency determination in pooled DNA samples by kinetic PCR.","volume":"10","author":"Germer","year":"2000","journal-title":"Genome Res"},{"key":"R18-6-20241201","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2011.050351","article-title":"IL28B polymorphisms influence stage of fibrosis and spontaneous or interferoninduced viral clearance in thalassemia patients with hepatitis C virus infection.","volume":"97","author":"Di Marco","year":"2012","journal-title":"Haematologica"},{"key":"R19-6-20241201","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10875-011-9547-1","article-title":"Role of interleukin 28B rs12979860 CT polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype.","volume":"31","author":"Falleti","year":"2011","journal-title":"J Clin Immunol"},{"key":"R20-6-20241201","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/hep.24678","article-title":"IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non1 HCV genotypes.","volume":"55","author":"Bochud","year":"2012","journal-title":"Hepatology"},{"key":"R21-6-20241201","first-page":"1220A","article-title":"Genome wideassociation study identifies IL28B polymorphism to be associated with baseline ALT and hepatic necroinflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study. Abstract.","volume":"52","author":"Thompson","year":"2010","journal-title":"Hepatology"},{"key":"R22-6-20241201","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.","volume":"45","author":"ProkuninaOlsson","year":"2013","journal-title":"Nat Genet"},{"key":"R23-6-20241201","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.23912","article-title":"IL28B genotype is associated with differential expression of intrahepatic interferonstimulated genes in patients with chronic hepatitis C.","volume":"52","author":"Urban","year":"2010","journal-title":"Hepatology"},{"key":"R24-6-20241201","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective followup study of 384 patients.","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"R25-6-20241201","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.510270535","article-title":"Determinants of outcome of compensated hepatitis C virusrelated cirrhosis.","volume":"27","author":"Serfaty","year":"1998","journal-title":"Hepatology"},{"key":"R26-6-20241201","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/hep.510290424","article-title":"The longterm outcomes of patients with compensated hepatitis C virusrelated cirrhosis and history of parenteral exposure in the United States.","volume":"29","author":"Hu","year":"1999","journal-title":"Hepatology"},{"key":"R27-6-20241201","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0952-7915(02)00354-0","article-title":"Links between innate and adaptive immunity via type I interferon.","volume":"14","author":"Le Bon","year":"2002","journal-title":"Curr Opin Immunol"},{"key":"R28-6-20241201","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hep.23624","article-title":"Interleukin28B genetic variants and hepatitis virus infection by different viral genotypes.","volume":"52","author":"MontesCano","year":"2010","journal-title":"Hepatology"},{"key":"R29-6-20241201","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1053\/j.gastro.2010.02.009","article-title":"Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.","volume":"138","author":"McCarthy","year":"2010","journal-title":"Gastroenterology"},{"key":"R30-6-20241201","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jhep.2011.03.015","article-title":"Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C.","volume":"55","author":"Tillmann","year":"2011","journal-title":"J Hepatol"},{"key":"R31-6-20241201","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1053\/j.gastro.2004.09.050","article-title":"Peginterferon alfa2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.","volume":"127","author":"Zeuzem","year":"2004","journal-title":"Gastroenterology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26506","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26506","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201311000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T14:14:42Z","timestamp":1733062482000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201311000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26506","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}